

32. (Twice Amended) The isolated polypeptide fragment of claim 31, wherein the isolated polypeptide fragment comprises a heterologous amino acid sequence fused to the at least 50 consecutive amino acids of SEQ ID NO:2.

33. (Twice Amended) An isolated polypeptide fragment comprising at least 30 consecutive amino acids of SEQ ID NO:2.

34. (Twice Amended) The isolated polypeptide fragment of claim 35, wherein the isolated polypeptide fragment comprises a heterologous amino acid sequence fused to the at least 30 consecutive amino acids of SEQ ID NO:2

---

#### Remarks

This amendment is responsive to the Office Communication mailed June 1, 2001 (Paper No. 8). Entry of this Amendment and reconsideration of the subject application in view thereof are respectfully requested.

#### Claims

Claims 25, 27, 29, 31-34 have been amended to more particularly and distinctly define the invention. No new matter is added.

#### Sequence Listing

The Examiner asserts that

[t]he reply filed on March 26, 2001 is not fully responsive to the prior Office action because of the following omission(s) or matter(s): Applicant's have amended the sequence to recite the amino acid sequence set forth in SEQ ID NO:1. However, while Applicant's paper copy of the sequence recites an amino acid sequence, Applicant's electronically submitted version of the sequences recites a nucleic acid sequence as SEQ ID NO:1. Appropriate correction is required.

Submitted herewith is a paper copy of a substitute "Sequence Listing" and a substitute computer readable form. The substitute paper copy of the sequence listing submitted herewith is identical

Serial No.: 09/292,411  
Group Art Unit: 1645

with the CRF also filed herewith. The substitute sequence listing is being submitted to obviate the asserted basis for the objection to the reply filed March 26, 2001. No new matter is added. Reconsideration and withdrawal of this objection are respectfully requested.


**FEE DEFICIENCY**

- ☒ If an extension of time is deemed required for consideration of this paper, please consider this paper to comprise a petition for such an extension of time; The Commissioner is hereby authorized to charge the fee for any such extension to Deposit Account No. 50-0258.
- and/or**
- ☒ If any additional fee is required for consideration of this paper, please charge Account No. 50-0258.

**Closing Remarks**

Applicant thanks the Examiner for the Office Action and believes this response to constitute a full and complete response to such Office Action. Accordingly, favorable reconsideration in view of this response and allowance of the pending claims are earnestly solicited.

Respectfully submitted,

  
Thomas S. Deibert  
Registration No. 40,984  
Attorney for Applicants

DECHERT PRICE & RHOADS  
Princeton Pike Corporate Center  
PO Box 5218  
Princeton, New Jersey 08543-5218  
Fax: (609) 620-3259  
Attn: Thomas S. Deibert, Esq.  
(609) 620-3231



Detail of claim amendments

25. (Twice Amended) An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2 [SEQ ID NO:1].
27. (Twice Amended) The isolated polypeptide of claim 25, wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the amino acid sequence set forth in SEQ ID NO:2 [SEQ ID NO:1].
29. (Twice Amended) The isolated polypeptide of claim 25, wherein the isolated polypeptide consists of the amino acid sequence set forth in SEQ ID NO:2 [SEQ ID NO:1].
31. (Twice Amended) An isolated polypeptide fragment comprising at least 50 consecutive amino acids of SEQ ID NO:2 [SEQ ID NO:1].
32. (Twice Amended) The isolated polypeptide fragment of claim 31, wherein the isolated polypeptide fragment comprises a heterologous amino acid sequence fused to the at least 50 consecutive amino acids of SEQ ID NO:2 [SEQ ID NO:1].
33. (Twice Amended) An isolated polypeptide fragment comprising at least 30 consecutive amino acids of SEQ ID NO:2 [SEQ ID NO:1].
34. (Twice Amended) The isolated polypeptide fragment of claim 35, wherein the isolated polypeptide fragment comprises a heterologous amino acid sequence fused to the at least 30 consecutive amino acids of SEQ ID NO:2 [SEQ ID NO:1].